The induction of labor in full-term pregnant females is a critical aspect of obstetric care aimed at mitigating important maternal and fetal risks correlated with prolonged pregnancies or medical conditions necessitating expedited delivery. Misoprostol [Miso], a synthetic prostaglandin E1 analog, has been promoted as a pharmacological agent for labor induction due to its effectiveness and ease of administration. Nonetheless, the optimal route of misoprostol administration remains a subject of ongoing debate. This comprehensive review systematically examines clinical trials, cohort trials, and randomized controlled trials (RCTs) to understand the comparative effectiveness of sublingual (SL) and vaginal (VAG) misoprostol for inducing labor in full-term pregnant females. Key findings reveal that both routes are adequate, with the choice dependent on patient-specific factors and preferences. Sublingual administration offers advantages regarding the faster onset of labor and reduced maternal fever risk but is associated with a higher incidence of shivering. Standardized dosing protocols, tailored to individual patient characteristics, are vital for safe and effective induction. Incorporating shared decision-making is integral for patient satisfaction and positive outcomes. Ultimately, the choice between SL and VAG misoprostol for labor induction should be guided by a comprehensive patient assessment in consultation with healthcare providers. Further research and clinical trials are needed to refine our understanding of these methods’ comparative efficacy and safety.